Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan.
Stage: preclinical
· pubmed
· 01-oct-2026
If you are tracking fisetin as the senolytic flavonoid, note that newer fisetin-derived analogs outperform it in mice — the human trials still underway are testing the weakest member of the family.
Novel fisetin-derived flavonoid senolytics SR29384 and SR31133 show enhanced senolytic activity across senescent cell types, reduce tissue senescence, and improve multiple healthspan markers in aging mouse models.
Link: /findings/1697